Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Down 6.4% in September
Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Down 6.4% in September
Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 126,000 shares, a decrease of 6.4% from the August 31st total of 134,600 shares. Based on an average daily trading volume, of 300 shares, the short-interest ratio is currently 420.0 days.
分子合作伙伴股份公司(OTCMKTS：MLLCF-GET Rating)看到空头股数在9月份大幅下降。截至9月15日，空头股数共有12.6万股，比8月31日的13.46万股减少了6.4%。以日均成交量300股计算，目前短息比为420.0天。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Separately, Credit Suisse Group reduced their price objective on shares of Molecular Partners from CHF 8 to CHF 6 in a research note on Thursday, July 21st.
另外，瑞士信贷集团在7月21日星期四的一份研究报告中将分子合伙公司的股票目标价从8瑞士法郎下调至6瑞士法郎。
Molecular Partners Trading Up 3.5 %
分子合作伙伴交易上涨3.5%
Shares of OTCMKTS:MLLCF opened at $6.29 on Monday. Molecular Partners has a 52-week low of $5.16 and a 52-week high of $32.00. The company has a 50-day simple moving average of $5.72 and a 200 day simple moving average of $9.26.
OTCMKTS：MLLCF的股票周一开盘报6.29美元。Molecal Partners的52周低点为5.16美元，52周高位为32.00美元。该公司的50日简单移动均线切入位在5.72美元，200日简单移动均线切入位在9.26美元。
Molecular Partners Company Profile
分子合作伙伴公司简介
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子伙伴公司是一家临床阶段的生物制药公司，专注于治疗性蛋白质的发现、开发和商业化。它的候选产品包括用于治疗新血管湿性老年性黄斑变性和糖尿病黄斑水肿的候选DARPin药物Abempar，该药物处于第三阶段临床试验；以及针对SARS-CoV-2病毒的多特异性DARPin候选药物MP0420。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免费获取StockNews.com关于分子伙伴的研究报告(MLLCF)
- 阿彻·丹尼尔斯·米德兰：49年增长的红利英雄
- 全自动拖拉机会让迪尔成为农业领域的特斯拉吗？
- 麦格纳国际是您的汽车和电动汽车一站式库存
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到分子合作伙伴的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收分子合作伙伴和相关公司的最新新闻和分析师评级的每日摘要。